Estrogen receptor status as a prognostic indicator for stage I breast cancer patients

Breast Cancer Res Treat. 1982;2(2):171-6. doi: 10.1007/BF01806453.


The prognostic value of estrogen receptor determination was studied for 510 stage I (axillary node negative) breast cancer patients treated by mastectomy alone. Results at 60 months after mastectomy indicate that stage I patients whose tumors lack estrogen receptors fall into a significantly poorer prognostic group for both recurrence and survival than those whose tumors contain estrogen receptors. Within the postmenopausal group, estrogen receptor negative (ER -) patients are recurring more rapidly than estrogen receptor positive (ER +) patients. Within the premenopausal group, ER + patients have a recurrence rate identical to ER - patients, which is apparent only after prolonged follow-up. In contrast to postmenopausal ER + patients, premenopausal ER + patients appear to have no prognostic advantage over the ER - patients, and thus constitute a high risk group for which adjuvant endocrine therapy might prove beneficial.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Breast Neoplasms / analysis*
  • Breast Neoplasms / surgery
  • Female
  • Humans
  • Lymphatic Metastasis
  • Mastectomy
  • Menopause
  • Neoplasm Recurrence, Local
  • Prognosis
  • Receptors, Estrogen / analysis*


  • Receptors, Estrogen